| Title |
T-cell receptor-engineered T cells for cancer treatment: current status and future directions
|
|---|---|
| Published in |
Protein & Cell, January 2017
|
| DOI | 10.1007/s13238-016-0367-1 |
| Pubmed ID | |
| Authors |
Yu Ping, Chaojun Liu, Yi Zhang |
| Abstract |
T-cell receptor (TCR)-engineered T cells are a novel option for adoptive cell therapy used for the treatment of several advanced forms of cancer. Work using TCR-engineered T cells began more than two decades ago, with numerous preclinical studies showing that such cells could mediate tumor lysis and eradication. The success of these trials provided the foundation for clinical trials, including recent clinical successes using TCR-engineered T cells to target New York esophageal squamous cell carcinoma (NY-ESO-1). These successes demonstrate the potential of this approach to treat cancer. In this review, we provide a perspective on the current and future applications of TCR-engineered T cells for the treatment of cancer. Our summary focuses on TCR activation and both pre-clinical and clinical applications of TCR-engineered T cells. We also discuss how to enhance the function of TCR-engineered T cells and prolong their longevity in the tumor microenvironment. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 5 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 265 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 265 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 51 | 19% |
| Student > Bachelor | 48 | 18% |
| Researcher | 34 | 13% |
| Student > Master | 30 | 11% |
| Student > Doctoral Student | 16 | 6% |
| Other | 27 | 10% |
| Unknown | 59 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 72 | 27% |
| Immunology and Microbiology | 39 | 15% |
| Agricultural and Biological Sciences | 35 | 13% |
| Medicine and Dentistry | 20 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 5% |
| Other | 20 | 8% |
| Unknown | 65 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2024.
All research outputs
#3,085,973
of 25,734,859 outputs
Outputs from Protein & Cell
#120
of 822 outputs
Outputs of similar age
#58,487
of 422,982 outputs
Outputs of similar age from Protein & Cell
#4
of 22 outputs
Altmetric has tracked 25,734,859 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 822 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,982 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.